Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) AI Stock Analysis

• Market Cap: HK$7.09B
• Dividend Yield: 0.82%
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): 35.9
• Beta (1Y): 1.17
• Revenue Growth: -32.05%
• EPS Growth: -54.47%
• Country: HK
• Employees: 1,237
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): 0.16
• Shares Outstanding: 95,140,500
• 10 Day Avg. Volume: 1,029,925
• 30 Day Avg. Volume: 1,338,908
• PEG Ratio: -1.26
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 335.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: HK$11.00 ▼(-14.73%Downside)

The overall stock score of 65 reflects the mixed performance of Beijing Chunlizhengda Medical Instruments Co., Ltd. The strong balance sheet provides stability, but declining revenue and negative cash flows pose significant risks. Technical analysis indicates bullish momentum, but valuation metrics suggest caution due to high P/E ratio.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Beijing Chunlizhengda Medical Instruments Co., Ltd., an orthopedic medical device company, engages in the research and development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China. It offers implantable orthopedic medical devices, which consist of joint prosthesis products and spinal products. The company primarily sells its products through distributors, or on ODM and OEM bases under the Chunli brand, as well as to hospitals directly. It also exports its products to various countries. The company was incorporated in 1998 and is headquartered in Beijing, China.

How the Company Makes Money

Beijing Chunlizhengda Medical Instruments Co., Ltd. generates revenue through the manufacture and sale of orthopedic medical devices. The company's primary revenue streams include the sale of joint prostheses and spinal implant products. These products are distributed to hospitals and healthcare providers in China and other international markets. The company invests in research and development to innovate and enhance its product offerings, ensuring compliance with regulatory standards and catering to the evolving needs of the healthcare industry. Strategic partnerships with medical institutions and expansion into new markets also play a crucial role in driving its sales and overall financial performance.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H exhibits strong balance sheet stability with minimal debt levels. However, the decrease in revenue and profitability margins, coupled with negative cash flow from operations, indicate potential financial stress. The company needs to address revenue generation and improve operational cash flows to sustain long-term growth.

Income Statement

The gross profit margin remains strong at 64.08% in 2024, indicating efficient cost management in production. However, revenue showed a significant decline of 33.33% from 2023 to 2024, indicating challenges in maintaining sales volumes. The net profit margin also decreased, reflecting reduced profitability. EBIT and EBITDA margins have also decreased, suggesting pressures on operational efficiency.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio of 0.0003, indicating minimal leverage and financial risk. The equity ratio is robust at 81.38%, showcasing strong financial stability. Despite a slight drop in stockholders' equity, the company's balance sheet remains strong.

Cash Flow

The operating cash flow turned negative in 2024, indicating issues in cash generation from core operations. Free cash flow has also declined, pointing to challenges in maintaining liquidity. The free cash flow to net income ratio is negative, highlighting the need for cash management improvements.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	805.86M	1.21B	1.20B	1.11B	937.69M
Gross Profit	516.49M	875.89M	913.53M	854.54M	680.76M
EBITDA	169.32M	340.65M	366.96M	360.99M	349.78M
Net Income	124.99M	277.82M	307.72M	322.36M	283.37M
Balance Sheet
Total Assets	3.47B	3.65B	3.41B	3.00B	1.54B
Cash, Cash Equivalents and Short-Term Investments	1.89B	2.10B	1.72B	1.74B	690.12M
Total Debt	866.44K	1.75M	1.31M	1.23M	1.85M
Total Liabilities	644.39M	770.33M	690.07M	530.58M	460.41M
Stockholders Equity	2.82B	2.88B	2.72B	2.47B	1.08B
Cash Flow
Free Cash Flow	-51.07M	478.47M	16.10M	-34.62M	236.68M
Operating Cash Flow	-1.90M	511.71M	41.01M	164.79M	260.68M
Investing Cash Flow	55.84M	-81.56M	―	―	―
Financing Cash Flow	-183.14M	-121.33M	―	1.07B	-11.88M

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Positive. The current price of 12.9 is above the 20-day moving average (MA) of 11.67, above the 50-day MA of 10.62, and above the 200-day MA of 8.96, indicating a bullish trend. The MACD of 0.54 indicates Negative momentum. The RSI at 67.63 is Neutral, neither overbought nor oversold. The STOCH value of 88.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1858.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1858	65 Neutral	HK$7.09B	35.93	4.39%	0.82%	-32.05%	-54.47%
Sector *	63 Neutral	CHF22.60B	15.13	10.81%	2.13%	47.85%	-11.82%
4WO		€500.81M	―	-10.43%	―	―	―
818		€742.79M	55.28	3.22%	0.59%	―	―
1789	75 Outperform	HK$6.78B	22.73	10.92%	1.19%	20.19%	45.54%
1763	73 Outperform	HK$4.76B	10.80	8.40%	4.55%	12.41%	―
1302	72 Outperform	HK$8.68B	36.88	6.49%	―	0.87%	-18.05%

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events

Beijing Chunlizhengda Declares Final Dividend for 2024

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the results of resolutions passed at their 2024 annual general meeting, including the declaration of a final ordinary cash dividend of RMB 0.49 per 10 shares for the financial year ending December 31, 2024. The dividend, approved on June 26, 2025, will be paid in Hong Kong dollars at a rate of HKD 0.5364 per 10 shares, with specific withholding tax rates applied based on shareholder residency. This announcement reflects the company’s commitment to returning value to its shareholders and may impact its financial performance and investor relations positively.

Beijing Chunlizhengda Medical Instruments Passes All Resolutions at 2024 AGM

Beijing Chunlizhengda Medical Instruments Co., Ltd. held its 2024 Annual General Meeting and A Shareholders’ Class Meeting on June 26, 2025, where all proposed resolutions were passed. The meeting was conducted in compliance with relevant regulations, and voting was overseen by WUYIGE Certified Public Accountants LLP. Key shareholders abstained from voting on certain resolutions, and there were no stated intentions to oppose any resolutions.

Beijing Chunlizhengda Medical Instruments Adjourns H Shareholders’ Meeting

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the adjournment of its H Shareholders’ Class Meeting due to insufficient voting rights participation. The meeting, initially scheduled for June 26, 2025, will now be held on July 7, 2025. This rescheduling ensures compliance with the company’s articles of association, allowing for adequate shareholder representation and decision-making.

Beijing Chunlizhengda Announces H Shareholders’ Class Meeting for Share Repurchase Mandate

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a class meeting for H shareholders to discuss a special resolution regarding the repurchase of H Shares. The proposed mandate would allow the board to repurchase up to 10% of the total H Shares, excluding treasury shares, based on market conditions and company needs. This move could potentially impact the company’s share capital structure and market positioning, reflecting strategic financial management to enhance shareholder value.

Beijing Chunlizhengda Schedules 2024 AGM with Key Resolutions on Agenda

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for June 26, 2025. Key resolutions to be discussed include the approval of the 2024 profit distribution plan, remuneration for directors and supervisors for 2025, and the re-appointment of auditors. Additionally, a special resolution will consider granting the board a mandate to repurchase up to 10% of its H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.

Beijing Chunlizhengda Announces Leadership Changes in Financial Management

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the resignation of two senior management members, Mr. Zhai Zhiyong and Ms. Li Yumei, due to personal reasons. Both will continue to serve the company in other capacities. The company appointed Ms. Lu Hongyue as the new Chief Financial Officer, effective immediately, to ensure continuity in financial management. This leadership change is expected to support the company’s ongoing financial strategies and operations.

Beijing Chunlizhengda Medical Instruments Reports Q1 2025 Financial Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. has released its unaudited financial results for the first quarter of 2025, in compliance with the Chinese Accounting Standards for Business Enterprises. The report, available in both Chinese and English, highlights the company’s financial performance for the three months ending March 31, 2025. Stakeholders are advised to consider potential investment risks as the data has not been audited.

Beijing Chunlizhengda Medical Instruments Announces Board Meeting for Quarterly Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced a board meeting scheduled for April 29, 2025, to approve the company’s first quarterly results for the period ending March 31, 2025, and to consider the payment of an interim dividend. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.